Spontonic

Ask your agent this question.... "Which germline or somatic NLRP3 variants that cause disease might respond to BGE-102 but not to agents which bind to the classic MCC950 site?" Just to get a clearer picture of how the $BIOA site is distinct, not proposing variants as indication.

$BIOA re. BGE-102

"Best in class potency"

"With essentially placebo-like tolerability"

"2045 composition of matter and claims for novel NLRP3 binding site"

event.summitcast.com/view/4aFtJriVa…

ZEUS in tomorrow's NEJM... "A second possibility raised by the contrasting findings in CANTOS and ZEUS is that interleukin-1β inhibition, but not interleukin-6 inhibition, lowers the risk of cardiovascular events." $BIOA $GLUE

1/ Despite all my pumping, I'd like to point out that my faves do no better than a XBI overlay on good days, and, last couple of years, worse than overlay on bad days. Biggest bets, silevertinib and CHS-114, have brought stunning clinical efficacy and nothing but pain for wallet.

I've got some $PEPG. I've got some $LQDA (thanks, Peter!). Etc. My PTGX position is up 600%. I hold many later- and commercial-stage biotechs. I just CHOOSE to talk about lost-soul, low EV ops. $BDTX $CNTB $BIOA